Cargando…
S100A1 blocks the interaction between p53 and mdm2 and decreases cell proliferation activity
About 50% of human cancers across the globe arise due to a mutation in the p53 gene which gives rise to its functional inactive form, and in the rest of the cancer the efficacy of active p53 (wild-type) is hindered by MDM2-mediated degradation. Breakdown of the p53-MDM2 association may constitute an...
Autores principales: | Dowarha, Deepu, Chou, Ruey-Hwang, Yu, Chin |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7272100/ https://www.ncbi.nlm.nih.gov/pubmed/32497081 http://dx.doi.org/10.1371/journal.pone.0234152 |
Ejemplares similares
-
S100P Interacts with p53 while Pentamidine Inhibits This Interaction
por: Katte, Revansiddha H., et al.
Publicado: (2021) -
Lysozyme as the anti-proliferative agent to block the interaction between S100A6 and the RAGE V domain
por: Khan, Md. Imran, et al.
Publicado: (2019) -
S100B as an Antagonist To Interfere with the Interface
Area Flanked by S100A11 and RAGE V Domain
por: Dowarha, Deepu, et al.
Publicado: (2018) -
Amlexanox Blocks the Interaction between S100A4 and Epidermal Growth Factor and Inhibits Cell Proliferation
por: Cho, Ching Chang, et al.
Publicado: (2016) -
S100B as an antagonist to block the interaction between S100A1 and the RAGE V domain
por: Khan, Md. Imran, et al.
Publicado: (2018)